Afamelanotide and NB-UVB Light
Phase 3Active 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Vitiligo
Conditions
Vitiligo
Trial Timeline
Oct 11, 2023 → Jun 1, 2026
NCT ID
NCT06109649About Afamelanotide and NB-UVB Light
Afamelanotide and NB-UVB Light is a phase 3 stage product being developed by Clinuvel Pharmaceuticals for Vitiligo. The current trial status is active. This product is registered under clinical trial identifier NCT06109649. Target conditions include Vitiligo.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06109649 | Phase 3 | Active |
Competing Products
20 competing products in Vitiligo